ScripUpdated results from Intellia Therapeutics and Regeneron ’s CRISPR Cas9-based in vivo gene-editing candidate NTLA-2001 have boosted confidence that it could be a major breakthrough in treating ge
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Amgen, Plexium Team Up Against Challeng